Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

Published:2013-10 Issue:15 Volume:49 Page:3111-3121
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Lee Dae Ho,Lee Jung Shin,Kim Sang-We,Rodrigues-Pereira José,Han Baohui,Song Xiang-Qun,Wang Jie,Kim Hoon-Kyo,Sahoo Tarini Prasad,Digumarti Raghunadharao,Wang Xin,Altug Sedat,Orlando Mauro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications;Chattopadhyay;Mol Cancer Ther,2007

2. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

3. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer;Scagliotti;J Thorac Oncol,2011

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21;Bezjak;J Clin Oncol,2006

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung cancer in never smokers (LCINS): development of a UK national research strategy;BJC Reports;2023-07-20

2. Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches;International Journal of Environmental Research and Public Health;2022-11-02

3. First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup Analysis;2022-09-01

4. Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials;Translational Lung Cancer Research;2021-05

5. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations;Clinical and Translational Science;2021-01-25